The European Medicines Agency announced March 19 that it has issued a positive opinion on the chemotherapy drug erlotinib as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer. Patients must have stable disease after 4 cycles of standard platinum-based first-line chemotherapy, the agency said in a written statement. Erlotinib (Tarceva, Roche) is an epidermal growth factor receptor (EGFR) inhibitor and is taken orally. It is currently indicated in the...